PTC Therapeutics, Inc.
PTC Therapeutics, Inc.
- Market cap
- $4.71B
Your view on PTCT
Overview
What the company does, where it operates, and who runs it.
About PTC Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew B. Klein F.A.C.S.,
- Headquarters
- 100 Corporate Court, Warren, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew B. Klein F.A.C.S.,
- Headquarters
- 100 Corporate Court, Warren, NJ, US
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.
The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F.
Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for PTC Therapeutics, Inc.. Starting points for PTC Therapeutics, Inc.: EPS -$1.27, beta 0.51 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for PTC Therapeutics, Inc.. Trailing twelve-month EPS for PTC Therapeutics, Inc. stands at -$1.27. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
9 firms, last 12 months- Strong Buy0
- Buy8
- Hold1
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.35 | $0.47 | $0.53 | $2.73 |
| Lowest estimate | −$3.73 | $0.28 | −$0.39 | $1.49 |
| Highest estimate | $5.20 | $0.66 | $0.99 | $4.47 |
| Number of analysts | 3 | 4 | 7 | 7 |
| A year ago | −$1.671 | −$0.031 | $7.781 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $330.38M | $316.83M | $1.32B | $1.43B |
| Lowest estimate | $309.50M | $295.00M | $1.30B | $1.33B |
| Highest estimate | $349.54M | $338.66M | $1.34B | $1.56B |
| Number of analysts | 8 | 3 | 10 | 10 |
| A year ago | $164.68M | $272.55M | $1.73B | — |
| Growth vs a year ago | +100.6% | +16.2% | −23.7% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for PTC Therapeutics, Inc.. PTC Therapeutics, Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BBIOBridgeBio Pharma, Inc. | Healthcare | Biotechnology | $14.8B | ||
| BMRNBioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $11.7B | ||
| CAPRCapricor Therapeutics, Inc. | Healthcare | Biotechnology | $439.6M | ||
| DYNDyne Therapeutics, Inc. | Healthcare | Biotechnology | $2.9B | ||
| IONSIonis Pharmaceuticals, Inc. | Healthcare | Biotechnology | $4.4B | ||
| KRYSKrystal Biotech, Inc. | Healthcare | Biotechnology | $9.2B | ||
| RAREUltragenyx Pharmaceutical Inc. | Healthcare | Biotechnology | $1.7B | ||
| SLDBSolid Biosciences Inc. | Healthcare | Biotechnology | $697.6M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| FTREFortrea Holdings Inc. | Healthcare | NASDAQ | $1.8B | ||
| FULCFulcrum Therapeutics, Inc. | Healthcare | NASDAQ | $281.8M | ||
| GALTGalectin Therapeutics Inc. | Healthcare | NASDAQ | $177.2M | ||
| GANXGain Therapeutics, Inc. | Healthcare | NASDAQ | $42.6M | ||
| GBIMGlobeImmune, Inc. | Healthcare | OTC | $575 | ||
| GBLXGB Sciences, Inc. | Healthcare | OTC | $122,121 | ||
| GDTCCytoMed Therapeutics Limited | Healthcare | NASDAQ | $8.9M | ||
| GENBGenerate Biomedicines, Inc. | Healthcare | NASDAQ | $1.2B | ||
| GENSFGenus plc | Healthcare | OTC | $2.5B | ||
| GERNGeron Corporation | Healthcare | NASDAQ | $560.9M | ||
| GHRSGH Research PLC | Healthcare | NASDAQ | $1.2B | ||
| GLABFGemina Laboratories Ltd. | Healthcare | OTC | $3.8M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IJRiShares Core SP Small-Cap ETF | $103.8B in assets | 0.29% | |
| XBIState Street SPDR S&P Biotech ETF | $10.0B in assets | 1.36% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.17% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.01% | |
| PSCHInvesco S&P SmallCap Health Care ETF | $188M in assets | 2.78% | |
| PBEInvesco Biotechnology & Genome ETF | $438M in assets | 2.27% | |
| JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF | $1.0B in assets | 1.00% | |
| JSMLJanus Henderson Small Cap Growth Alpha ETF | $379M in assets | 0.93% | |
Largest holders first, then the funds most concentrated in PTCT.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold PTC Therapeutics, Inc., and how their positions are changing. At a $4.71B market value, institutional positions materially move PTC Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by PTC Therapeutics, Inc. executives and directors. Shares of PTC Therapeutics, Inc. have traded between $35.95 and $77.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for PTC Therapeutics, Inc.. Coverage tracks PTC Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of PTC Therapeutics, Inc.